Arcutis Biotherapeutics, Inc.
ARQT
ARQTArcutis Biotherapeutics, Inc.
NASDAQ Global SelectCIK
0001787306
ISIN
US03969K1088
CUSIP
03969K108
Return %
Stock
S&P500
1Y
309.43
26.64
3Y
-15.01
31.02
5Y
-37.27
80.18
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mr. Todd Franklin Watanabe M.A.
- Full Time Employees
- 296
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3027 Townsgate Road Westlake Village CA United States of America 91361
- IPO Date
- Jan 31, 2020
- CIK
- 0001787306
- Website
- arcutis.com
- Similar Companies
- Business
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.